@article{0c750374bb2e4fc9aea2724fbb7649dc,
title = "Racial differences in CT phenotypes in COPD",
abstract = "Background: Whether African Americans (AA) are more susceptible to COPD than non-Hispanic Whites (NHW) and whether racial differences in disease phenotype exist is controversial. The objective is to determine racial differences in the extent of emphysema and airway remodeling in COPD. Methods: First, 2,500 subjects enrolled in the COPDGene study were used to evaluate racial differences in quantitative CT (QCT) parameters of% emphysema, air trapping and airway wall thickness. Independent variables studied included race, age, gender, education, BMI, pack-years, smoking status, age at smoking initiation, asthma, previous work in dusty job, CT scanner and center of recruitment. Results: Of the 1,063 subjects with GOLD Stage II-IV COPD, 200 self-reported as AA. AAs had a lower mean% emphysema (13.1% vs. 16.1%, p = 0.005) than NHW and proportionately less emphysema in the lower lung zones. After adjustment for covariates, there was no statistical difference by race in air trapping or airway wall thickness. Measured QCT parameters were more predictive of poor functional status in NHWs compared to AAs. Conclusions: AAs have less emphysema than NHWs but the same degree of airway disease. Additional factors not easily assessed by current QCT techniques may account for the poor functional status in AAs.",
keywords = "Air trapping, Airway wall thickness, Chronic obstructive pulmonary disease, Emphysema, Quantitative CT, Race",
author = "Hansel, {Nadia N.} and Washko, {George R.} and Foreman, {Marilyn G.} and Han, {Meilan K.} and Hoffman, {Eric A.} and Demeo, {Dawn L.} and Barr, {R. Graham} and {Van Beek}, {Edwin J.R.} and Kazerooni, {Ella A.} and Wise, {Robert A.} and Brown, {Robert H.} and Jennifer Black-Shinn and Hokanson, {John E.} and Hanania, {Nicola A.} and Barry Make and Silverman, {Edwin K.} and Crapo, {James D.} and Dransfield, {Mark T.}",
note = "Funding Information: The project described was supported by Award Number U01HL089897 and Award Number U01HL089856 from the National Heart, Lung, And Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute or the National Institutes of Health. Funding Information: Conflict of Interests: MKH has performed consulting for Nycomed and Novartis; participated on advisory boards for Novartis, Genentech, GlaxoSmithKline, Pfizer, Boehringer Ingelheim and MedImmune; and, participated on speaker bureaus for GlaxoSmithKline, Boehringer Ingelheim and Pfizer. BM has participated in advisory boards, speaker bureaus, consultations and multi-center clinical trials related to COPD with funding from the National Heart Lung and Blood Institute, Abbott, Astel-las, AstraZeneca, Boerhinger-Ingelheim, Dey, Embryon, Forest, GlaxoSmithKline, NABI, NyComed, Novartis, Pfizer, Respironics, Schering, Sequal and Talecris. He has no direct conflicts with the topic of this manuscript. EKS received grant support and consulting fees from Glaxo-SmithKline for studies of COPD genetics; and received honoraria and consulting fees from AstraZeneca. All other authors – none. All authors are responsible for the content and writing of this paper.",
year = "2013",
month = feb,
doi = "10.3109/15412555.2012.727921",
language = "English (US)",
volume = "10",
pages = "20--27",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "1",
}